Skip to main content

Table 3 S. pneumoniae, S. pyogenes, S. agalactiae, and Viridans group streptococci isolated from ICU patients during 2000–2002

From: Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002)

  

United States

Canada

Italy

Germany

Francea

Organism

Agent

Total n

%S

%R

Total n

%S

%R

Total n

%S

%R

Total n

%S

%R

Total n

%S

%R

Streptococcus pneumoniae

Amoxicillin

120

91.7

2.5

31

100

0

60

93.3

6.7

17

100

0

1,328

71.2

2.3

 

Cefepime

22

90.9

4.5

25

60.0

12.0

66

90.9

7.6

NTb

NT

NT

<10

NAc

NA

 

Cefotaxime

1,571

82.2

6.3

145

93.8

0.7

108

93.5

4.6

63

100

0

1,181

77.1

0.8

 

Ceftriaxone

2,373

88.3

3.2

145

91.7

0.7

145

91.7

3.4

29

100

0

544

80.1

0.6

 

Clarithromycin

184

71.7

25.5

56

69.6

30.4

90

64.4

31.1

<10

NA

NA

NT

NT

NT

 

Erythromycin

3,029

67.9

30.5

539

78.5

20.8

313

69.6

28.1

405

88.6

9.4

1,567

59.0

38.8

 

Levofloxacin

2,133

99.1

0.4

356

98.6

1.1

174

98.3

0.6

340

99.4

0.3

62

98.4

1.6

 

Penicillin

3,096

51.5

20.2

325

59.1

7.1

198

77.3

7.6

102

96.1

2.0

1,387

45.5

17.9

 

Vancomycin

2,865

100

-c

271

100

-

231

100

-

190

100

-

1,479

100

-

Streptococcus pyogenes

                
 

Amoxicillin

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

58

100

0

 

Cefepime

<10

NA

NA

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

 

Cefotaxime

32

100

-

29

100

-

<10

NA

NA

11

100

-

30

100

-

 

Ceftriaxone

75

100

-

<10

NA

NA

<10

NA

NA

<10

NA

NA

<10

NA

NA

 

Clarithromycin

19

84.2

5.3

<10

NA

NA

17

88.2

11.8

NT

NT

NT

NT

NT

NT

 

Erythromycin

118

92.4

6.8

102

81.4

11.8

59

74.6

23.7

63

84.1

11.1

170

82.9

14.7

 

Levofloxacin

71

97.2

1.4

<10

NA

NA

<10

NA

NA

61

77.0

4.9

NT

NT

NT

 

Penicillin

140

100

-

97

100

-

58

100

-

64

100

-

139

100

-

 

Vancomycin

121

100

-

42

100

-

12

100

-

34

100

-

162

100

-

Streptococcus agalactiae

                
 

Amoxicillin

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

165

100

0

 

Cefepime

28

100

-

NT

NT

NT

<10

NA

NA

NT

NT

NT

NT

NT

NT

 

Cefotaxime

71

100

-

17

100

-

24

100

-

50

100

-

50

100

-

 

Ceftriaxone

184

100

-

<10

NA

NA

38

100

-

37

100

-

<10

NA

NA

 

Clarithromycin

21

81.0

9.5

<10

NA

NA

21

71.4

28.6

NT

NT

NT

<10

NA

NA

 

Erythromycin

489

76.3

21.7

222

82.9

14.9

121

77.7

18.2

192

83.9

10.9

588

79.9

16.2

 

Levofloxacin

333

97.9

1.2

<10

NA

NA

51

98.0

0

180

91.1

1.7

173

99.4

0

 

Penicillin

518

100

-

226

100

-

145

100

-

184

100

-

369

100

-

 

Vancomycin

463

100

-

179

100

-

143

100

-

65

100

-

526

100

-

Streptococcus viridans group

                
 

Amoxicillin

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

268

92.9

0.7

 

Cefepime

23

95.7

4.3

NT

NT

NT

12

66.7

33.3

NT

NT

NT

NT

NT

NT

 

Cefotaxime

434

83.6

11.1

101

92.1

4.0

31

90.3

9.7

75

97.3

2.7

56

94.6

0

 

Ceftriaxone

678

87.3

7.7

130

89.2

3.8

99

81.8

18.2

40

97.5

2.5

<10

NA

NA

 

Clarithromycin

34

52.9

38.2

21

76.2

19.0

21

71.4

23.8

<10

NA

NA

NT

NT

NT

 

Erythromycin

959

57.2

37.7

289

71.6

23.2

192

64.6

32.8

796

88.1

9.2

626

59.9

31.6

 

Levofloxacin

331

96.1

2.7

<10

NA

NA

16

87.5

0

93

89.2

4.3

<10

NA

NA

 

Penicillin

1,047

63.7

6.2

303

79.2

0

61

78.7

8.2

<10

NA

NA

452

69.0

3.1

Vancomycin

1,095

100

-

276

100

-

180

100

-

277

100

-

580

100

-

 
  1. aNCCLS breakpoints were used for all countries, except France (CA-SFM) bNot tested cBreakpoints do not currently exist to interpret as S (susceptible) or R (resistant)